About enfortumab
Nectin-4-directed antibody-drug conjugate
Used for
- Advanced or metastatic urothelial cancer, alone or with pembrolizumab.
- Muscle-invasive bladder cancer with pembrolizumab in certain treatment settings.
Usual adult dose
For advanced cancer alone or with pembrolizumab: 1.25 mg/kg intravenously on days 1 and 8 of each 21-day cycle, maximum 125 mg per dose. For muscle-invasive bladder cancer with pembrolizumab: 1.25 mg/kg on days 1 and 8 of each 21-day cycle; regimen-specific schedules apply.
Common side effects
- Rash and other skin reactions
- Peripheral neuropathy
- High blood sugar
- Fatigue, nausea, diarrhea, or reduced appetite
Important warnings
- Severe skin reactions, including rare life-threatening reactions, can occur.
- High blood sugar can be severe, including diabetic ketoacidosis.
- Peripheral neuropathy may require treatment interruption or dose reduction.
- Serious infections, eye problems, and infusion-site reactions can occur.
Pregnancy
May cause fetal harm. Pregnancy testing and effective contraception are recommended during treatment and for two months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for at least three weeks after the last dose.
Interactions
- No major established drug interactions; pembrolizumab is commonly given with enfortumab vedotin.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.